Lexicon Pharma (LXRX) Tops Q4 EPS by 14c, Beats on Revenues
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.34 +0.86%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
ELWT, CAAP, RNW, More
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
ELWT, CAAP, RNW, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.27), $0.14 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $33 million versus the consensus estimate of $29.98 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- BofA Securities Downgrades Autohome Inc. (ATHM) to Underperform
- KeyBanc Upgrades Acadia Realty Trust (AKR) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
